This legitimises Mesoblast now and as they eluded when talking about Ruxolitinib, that company had a history which they said was the reason for easier approval.
This isn't just a typical approval, this is the first approval for this company in a novel and revolutionary way of treating disease.
The sky has opened and with the line up Mesoblast has in Phase III readouts, if they show efficacy, this recent result is extremely helpful.
Trading strategies for tomorrow morning?, page-7
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |